Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 750 clinical trials
None
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus

This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.

lupus
  • 2 views
  • 26 Jan, 2021
  • 1 location
None
Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation

Diagnosis and follow up of a lupus cohort in a multidisciplinary consultation in Brest ( France)

  • 0 views
  • 28 Jan, 2021
  • 1 location
None
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients

This is an open-label, one-arm single-center phase a study exploring the efficacy and safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) in two subpopulation group of systemic lupus erythematosus patients - lupus nephritis and lupus cytopenia.

  • 0 views
  • 16 Apr, 2021
  • 1 location
None
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases

Accelerated atherosclerosis is an established complication of systemic autoimmune diseases, particularly SLE. Young female patients with SLE are more likely to develop myocardial infarction than matched healthy controls, and CVD is nowadays one of the most common causes of death (27%) in lupus patients. While traditional CV risk factors cannot …

  • 0 views
  • 19 Mar, 2021
  • 4 locations
None
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent influenza vaccine in patients with Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will be treated with anifrolumab in addition to standard of care lupus treatments …

  • 0 views
  • 05 Dec, 2021
  • 5 locations
None
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)

lupus
antinuclear antibody
  • 0 views
  • 31 May, 2021
  • 13 locations
None
Study of Anti-Malarials in Incomplete Lupus Erythematosus

This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features. Effects on clinical progression of symptoms, patient-reported outcomes and changes in the immune markers of response …

hydroxychloroquine
arthritis
antinuclear antibody
antimalarials
lupus
  • 114 views
  • 09 Nov, 2021
  • 7 locations
None
Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Homocystinuria caused by Cystathionine Beta-Synthase (CBS) Deficiency is a rare autosomal-recessive metabolic condition characterized by an excess of homocysteine (Hcy) in the plasma, tissues and urine. It is due to reduced or absent activity of the CBS enzyme, and is also known as classical homocystinuria. The symptoms associated with homocystinuria …

  • 19 views
  • 12 Sep, 2021
  • 12 locations
None
Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

The DupiMorph study evaluates the efficacy of Dupilumab in localized scleroderma patients. Dupilumab is approved in the US and EU for the treatment of moderate/severe atopic dermatitis and since 2018 in the US for severe asthma therapy.

  • 33 views
  • 27 Oct, 2021
  • 3 locations
None
Treatment of Dupuytren's Disease With Minimal Invasive Surgery and VIVOSORB Resorbable Implant Device

Dupuytren's disease is a progressive fibroproliferative condition of the hand which progresses in 20% of patients into a serious condition. In Flanders, Dupuytren's disease was found to be present in 32% of the population over 50 years. In severe flexion contracture finger deformity due to Dupuytren's disease, functional loss of …

  • 3 views
  • 26 Jan, 2021
  • 1 location